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Abstract
We investigated the impact of immune regulatory mechanisms involved in the modulation of the recently presented, CD8+
lymphocyte mediated immune response in a mouse model of oligodendropathy-induced inflammation (PLPtg-mutants).
The focus was on the role of the co-inhibitory molecule PD-1, a CD28-related receptor expressed on activated T- and B-
lymphocytes associated with immune homeostasis and autoimmunity. PLPtg/PD-1-deficient double mutants and the
corresponding bone marrow chimeras were generated and analysed using immunohistochemistry, light- and electron
microscopy, with particular emphasis on immune-cell number and neural damage. In addition, the immune cells in both the
CNS and the peripheral immune system were investigated by IFN-gamma elispot assays and spectratype analysis. We found
that mice with combined pathology exhibited significantly increased numbers of CD4+ and CD8+ T-lymphocytes in the CNS.
Lack of PD-1 substantially aggravated the pathological phenotype of the PLPtg mutants compared to genuine PLPtg
mutants, whereas the PD-1 deletion alone did not cause alterations in the CNS. CNS T-lymphocytes in PLPtg/PD-1-/- double
mutants exhibited massive clonal expansions. Furthermore, PD-1 deficiency was associated with a significantly higher
propensity of CNS but not peripheral CD8+ T-cells to secrete proinflammatory cytokines. PD-1 could be identified as a
crucial player of tissue homeostasis and immune-mediated damage in a model of oligodendropathy-induced inflammation.
Alterations of this regulatory pathway lead to overt neuroinflammation of high pathogenetic impact. Our finding may have
implications for understanding the mechanisms leading to the high clinical variability of polygenic or even monogenic
disorders of the nervous system.
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Introduction
We have recently investigated a mouse myelin mutant
overexpressing the proteolipid protein (PLP) in oligodendrocytes
leading to myelin degeneration and late onset axonal degenera-
tion. Although being primarily caused by the glial mutation, the
neuropathological phenotype was accompanied by an elevation of
CD11b+ macrophages and CD8+ T-lymphocytes in the central
nervous system [1]. Reconstitution experiments with RAG-1
deficient myelin mutants, receiving bone-marrow from either
CD8+/CD42 or CD82/CD4+ mutants, clearly identified CD8+
T-lymphocytes cells as pathogenic mediators. Lack of the
macrophage-restricted molecule sialoadhesin in the PLP mutants,
that mediates interactions of macrophage-like cells and T-
lymphocytes [2], abrogates the elevation of CD8+ T-lymphocytes
and substantially ameliorates the myelin-phenotype of the PLP
mutants, further supporting the pathogenetic role of CD8+ cells in
PLP transgenic mice [3]. In this model, CD8+ lymphocytes show
clonal expansions in the diseased CNS but not in peripheral
lymphatic organs. This serves as a strong hint for a pathogenetic,
antigen-specific role of these cells [4]. The link between
oligodendrocyte damage and components of the adaptive immune
system is particularly relevant for inflammatory disorders of the
nervous system. It has been recently hypothesized that subtypes of
multiple sclerosis (MS) may be caused by a primary oligodendro-
pathy [5,6]. This hypothesis is strongly supported by recent clinical
reports, showing that PLP mutations in humans can be linked to
primary progressive or relapsing-remitting MS [7,8]. Thus, our
recentworkidentifyingaprimaryoligodendropathyasa‘‘trigger’’for
immune-driven pathological changes is important for our under-
standing of pathomechanisms occurring in some forms of MS.
It is well known, that genetic and environmental factors control
disease onset and disease course of CNS inflammatory autoim-
mune disorders [9]. The co-inhibitory molecule ‘‘programmed
death’’ (PD)-1 (CD279) is a CD28-related receptor expressed on
activated T- and B-lymphocytes and associated with immune
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demonstrated that a polymorphism of the PD-1 gene is associated
with a progressive disease course in MS [12], therefore
corroborating the importance of PD-1 as a disease modifying
gene. Moreover, inactivation of PD-1 in an animal model for
inherited demyelination in the peripheral nervous system impli-
cating T-lymphocytes [13] leads to a substantial aggravation of the
primarily genetically-caused neuropathy [14].
In the present study, we investigate the impact of immune-
regulatory mechanisms involved in the modulation of the immune
response in PLP transgenic mice, a model of oligodendropathy-
induced inflammation. Our present study identifies PD-1 as a
crucial factor regulating tissue homeostasis of T-lymphocytes and
indicates that a primary oligodendropathy combined with
alterations in this regulatory pathway can lead to accelerated
neuroinflammatory reactions of high pathogenetic impact.
Materials and Methods
Animals and Determination of Genotypes
PLP transgenic mice [15] were bred and genotyped as described
previously [1]. PD-1-/- mice [16] were kindly provided by T.
Honjo and C. Blank. Absence of PD-1 was verified by PCR
genotyping as described [14]. To generate double mutants, PLPtg
and PD-1-/- mice were crossbred. All resulting genotypes were
investigated at 2, 6 and 12 months of age.
To exclude organ autoimmunity in the PD-1-/- mice [16], urine
samples were investigated for protein and glucose with CombiS-
creenH urine tests (BioconDiagnostik, Voehl-Marienhagen, Ger-
many). For bone marrow chimerization, PLPtg/RAG-1-/- mice
were used as recipients. RAG-1 deficiency was identified as
previously described [1,14,17].
All mice were bred and kept in our animal facility under barrier
conditions (University of Wuerzburg, Department of Neurology).
All animal experiments were approved by the local authorities
(Regierung von Unterfranken).
Bone marrow chimerization
Two strategies to generate bone marrow chimeras were
performed: In one group, the recipients (PLPtg mice with PLPwt
mice as controls) were sublethally irradiated (5 Gy), while mice in
the other group were deficient for the recombination activating
gene (RAG)-1 (PLPtg/RAG-1-/- recipients with PLPwt/RAG-
1-/- as controls). The bone marrow chimeras were transplanted
with PD-1-/- or wildtype bone marrow at the age of 6–8 weeks
and investigated at the age of 10 months (n=8–9). Transplanta-
tion and control of successful transplantation was performed as
described before [1,18,19].
Purification of splenocytes
Spleens were passed through a cell strainer (BD Biosciences
Pharmingen, San Jose, CA USA), erythrocytes were lysed with a
lysis buffer (150mM NH4Cl2, 10 mM KHCO3, 0.1 mM EDTA in
distilled water at pH 7.3) and cells were washed and processed for
the respective experiments.
Preparation of CNS mononuclear cells and flow
cytometry of splenocytes and CNS lymphocytes
Mice were killed with CO2 and transcardially perfused with cold
0.1 M PBS. The CNS was prepared, tissues were homogenized
and cells were gradient isolated as described [1]. Flow cytometry
was performed using standard methods as described [4,20].
Tissue preparation and immunohistochemistry
For identification of macrophage-like cells, mice were transcar-
dially perfused with 4% paraformaldehyde in 0.1 M cacodylate
buffer. Tissue was dissected, postfixed for 2 hours and cryopro-
tected in 30% sucrose overnight. For T- lymphocyte and MBP
staining, mice were perfused with 0.1 M phosphate buffered saline
(PBS) only. After snap freezing, 10 mm thick transverse sections of
the spinal cord and longitudinal or transverse sections of the optic
nerve were cut.
Immunohistochemistry for CD11b, Sialoadhesin, CD4, CD8
and MBP was performed as described before [1,3]. MBP was
stained on optic nerve cross sections 1200–1400 mm caudal to the
retina. Sources of reagents, of antibodies and clones of the
antibodies were the same as described [1,3].
Assessment of demyelination
Myelin damage in optic nerve cross sections was assessed by
measuring MBP negative areas, data were displayed as a
percentage of the total area. For this, we used a Zeiss Axiophot2
microscope at a final magnification of 3006. The area was
measured using digital images acquired via a CCD- camera and
ImagePro 4.0 software.
Additionally, myelin damage was semiquantitatively rated as
described before [1], with score 1 depicting homogeneous MBP
distribution, score 5 massive myelin loss.
Tissue preservation for light microscopy of semithin
sections
Optic nerves from transcardially perfused mice were processed
for light microscopy of semithin sections as recently reported [1].
Tissue damage was assessed by quantification of axonopathic
vacuoles .6 mm.
Quantification of immune cells in the CNS
Longitudinal sections of the optic nerve of 2, 6 and 12 months
old wildtype, PD-1-/-, PLPtg and PLPtg/PD-1-/- mice and
10 months old bone marrow chimeras were analysed. Quantifi-
cation of CD11b+ and Sialoadhesin (Sn)+ cells was performed as
described before [1] in the rostral region. CD4+ and CD8+ T-cells
were quantified in total longitudinal optic nerve sections, using a
Zeiss Axiophot2 microscope and measurement tools as described
above.
Detection of cytokines by ELISA and ELISPOT
1610
6/ml splenocytes were cultured unstimulated or stimulated
with ConA (2 mg/ml, Sigma, Schnelldorf, Germany) or CD3/
CD28 coated microspheres (Dynal, Invitrogen, Karlsruhe, Ger-
many). After 48 hours, supernatant was harvested and ELISA for
IFN-c, IL-2 or IL-10 (R&D Systems, Minneapolis, MN, USA) was
performed according to the manufacturers instructions.
Assessment of interferon-gamma (IFN-c) producing cells was
performed by ELISPOT. 1x10
4 CNS lymphocytes or 1610
5
splenocytes per well were incubated for 24 hours, unstimulated or
stimulated with PMA (20 ng/ml)/Ionomycin (500 ng/ml, both
Sigma), or a mixture of class one PLP, MOG and MBP peptides
(Genscript Corp, Piscataway, NJ, USA) as previously described
[4]. ELISPOT assay was performed according to the manufac-
turers instructions (BD Pharmingen). Spots were quantified by
CTL Europe (Aalen, Germany) using ImmunoSpot 4.0.17.
CDR3 Spectratyping
The CDR3 spectratyping was performed as described previ-
ously [4,21] using an ABI Prism 3130 capillary sequencer (Applied
PD-1 in Hereditary Gliopathy
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for fragment-analysis. As an internal length standard, 500-ROX
(Applied Biosystems) was used.
Statistical analysis
Quantified profiles were tested with two-tailed student’s t-test,
scores were analyzed by the nonparametric Mann-Whitney-U test
and Kruskal-Wallis test.
Results
The role of PD-1, a co-inhibitory molecule critical for immune
homeostasis and tolerance, was tested in a model of CNS-
myelinopathy associated with secondary, low grade inflammation
of high pathological relevance.
Numbers of CNS immune cells are significantly elevated
in PLPtg/PD-1-/- double mutants
To obtain myelin mutants with inactivated PD-1 function, two
strategies have been chosen. First, double mutants have been
created in analogy to previous experiments [1,3] by crossbreeding
the corresponding single mutants. This strategy has the advantage
that all cells of the organism lack PD-1. Complementarily, bone
marrow chimeric mutants have been generated using either
irradiated or RAG-1-deficient PLPtg mice as recipients and PD-
1-/- mice as donors [1,18]. The latter strategy has the advantage
that unexpected side effects or influences of the systemic PD-1-
inactivation (e.g. influences of PD-1 deficiency on thymic
maturation or neonatal tolerance) can be circumvented.
PLPtg/PD-1-/- double mutants and their respective controls
(wt, PD-1-/- and PLPtg mice), were examined at the age of 2, 6
and 12 months (n=3–7). To quantify immune cells in the CNS,
we focussed on longitudinal sections of the optic nerve, an already
established read out technique for the scoring of inflammation in
PLP mutant CNS [1,3,22].
At the age of two months, there was no significant difference
between wt, PD-1-/-, PLPtg and PLPtg/PD-1-/- mice. At
6 months, however, there was a slight elevation of CD8+ T- cells
in the optic nerve of PLPtg mice in comparison to wildtype mice,
consistent with our previous observations. PD-1-/- also showed a
mild elevation, whereas PLPtg/PD-1-/- double mutant mice
exhibited a robust upregulation of CD8+ T-cells in optic nerve
sections (approximately 35-fold increase compared to wildtype
mice and a more than 8 fold increase in comparison to PLPtg
mice, Figure 1A). In 12 months old mice, the general pattern of
CD8+ lymphocyte numbers in optic nerves was similar in the
different genotypes, but proportions had shifted a little: wt and
PD-1-/- mice were now at similar levels (with no marked increase
of profiles in PD-1-/- mice compared to the 6 months old group),
and PLPtg mice displayed significantly more CD8+ profiles than
the former two genotypes. Strikingly, these CD8+ T-lymphocytes
were again clearly outnumbered by those from PLPtg/PD-1-/-
mice (Figure 1B, C).
CD4+ T-lymphocytes are rarely present in the CNS of PLPtg
and wt mice [1]. At the age of two months, no differences were
detectable in all investigated groups.
At the age of 6 months a significant elevation of CD4+
lymphocytes was already visible in PLPtg/PD-1-/- compared to
wt, PD-1-/- and PLPtg mice and there was no marked increase
until the age of 12 months (Figure 1D). Similar changes in T-
lymphocyte numbers were detected in the spinal cord (data not
shown).
Furthermore, we investigated the number of CD11b+ macro-
phage-like cells in the optic nerve. We did not detect significant
differences at the age of 2 or 6 months, although a trend of
increased numbers was already detectable in PLPtg mice and
PLPtg/PD-1-/- double mutants at 6 months (data not shown). In
12 months old mice, however, a difference was detectable. While
wt and PD-1-/- mice showed a common low level of cells, both
PLPtg and PLPtg/PD-1-/- mice had elevated numbers of
CD11b+ cells (Figure 1E).
We additionally investigated the number of Sialoadhesin (Sn)
expressing macrophage like cells in 12 months old PLPtg/PD-1-/-
mice and detected a very low amount of positive profiles in both
wildtype and PD-1-/- mice. In PLPtg, a more than ten-fold
increase was detectable, but there was no significant difference
between PLPtg and PLPtg/PD-1-/- mice (data not shown).
Numbers of immune cells are significantly elevated in
PLPtg PD-1-/- transplanted bone marrow chimeras
(BMCs)
Another strategy to investigate the role of PD-1 in PLPtg mice
was to examine PLPtg mice which were transplanted with bone
marrow from either PD-1-/- mice (PLPtg BMC PD-1-/-) or
wildtype mice (PLPtg BMC wt). Wildtype mice which were
transplanted with either wildtype or PD-1-/- bone marrow served
as controls. These animals never displayed myelin pathology or
CNS inflammation in any experiment.
The bone marrow chimeric mice faithfully reflected the findings
described for the double mutants. For example, both irradiated
and PLPtg/RAG-1-/- recipients showed a robust upregulation of
CD8+ lymphocytes, when bone marrow was derived from PD-
1-/- mice (Figure 1F). Similar observations were made for the low
but significantly elevated amount of CD4+ cells (data not shown).
Increased elevation of CD8+ and CD4+ cells in the absence of
PD-1 was significant both in irradiated and in RAG-1-deficient
PLPtg mice.
Analysis of CD11b+ macrophage like cells depicted a small,
significant increase in PLPtg PD-1-/- transplanted chimeras
compared to recipients that received bone marrow from wildtype
mice (data not shown). In the irradiated PLPtg mice statistical
significance was reached, while the PLPtg/RAG-1-/- mice showed
a trend into the same direction but did not reach the level of
significance (p=0.06).
Pathological features are enhanced in PLPtg/PD-1-/-
double mutated mice
MBP immunohistochemistry revealed that, while wildtype and
PD-1-/- mice always showed a homogeneous distribution of
myelin, PLPtg mice displayed a more patchy and inhomogeneous
MBP staining. Compared to that, PLPtg/PD-1-/- mice showed an
even less homogeneous MBP distribution, reflecting extensive
myelin loss (Figure 2A).
Interestingly, in one PLPtg/PD-1-/- optic nerve we observed an
extended and sharply confined area of MBP-loss, reminiscent of a
demyelinated lesion common to active or inactive MS plaques
(Figure 2B). This lesion was associated with an accumulation of
CD8+ lymphocytes (Figure 2C) and hematoxylin-stained cells of
probably inflammatory character (Figure 2D).
To quantify the demyelinating phenotype of the different
mutants, MBP-negative areas of optic nerve cross sections were
determined as measure for demyelination. Neither wildtype nor
PD-1-/- mice showed any MBP-negative areas, while demyelin-
ation was present in PLPtg mice and further significantly increased
in PLPtg/PD-1-/- mice (Figure 2E). Additionally, myelin integrity-
related MBP distribution was analysed by semi-quantitative
scoring. Again, wt and PD-1-/- mice showed healthy myelin
PD-1 in Hereditary Gliopathy
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PLPtg/PD-1-/- mice showed a higher score (3.8360.75). PD-1-
deficiency leads to the highest MBP loss in the myelin mutants and
the most seriously affected mutants belong to the PD-1-deficient
group. Generally, the persons investigating the histopathological
features (A. K., R. M.) were not aware of the respective genotypes.
Similar to these results in double mutant mice, 10 months old
PLPtg BMCs reconstituted with PD-1-/- bone marrow showed a
more disrupted state of MBP distribution than PLPtg mice
transplanted with BMCs from wt mice (data not shown).
We also investigated periaxonal vacuoles in semithin cross
sections of the optic nerve as another reliable pathological marker
[1,3] (age of 12 months in double mutants, age of 10 months in
bone marrow chimeras). PLPtg/PD-1-/- double mutants, com-
pared to PLPtg mice, showed a clear trend of increased vacuole
numbers (13.367.9 versus 7.9563.6), while wt and PD-1-/- mice
never displayed any vacuoles (data not shown).
PLPtg BMCs transplanted with PD-1-/- bone marrow showed a
highly significant increase of axonal damage (Figure 2F, G, H). In
the optic nerves of wildtype mice, we never detected any vacuoles,
regardless what kind of bone marrow had been transplanted.
T-cell CDR3 spectratype analysis: robust clonal
expansions in the CNS of PLPtg/PD-1-/- mice
Evidence for monoclonal T-cell expansions as revealed by single
Vb-Jb peaks in the corresponding PCR-diagrams could be
detected (one Vb peak per animal) in 12-month-old PLPtg mice
corroborating these previous findings [4]. Corresponding expan-
sions could not be detected in spectratyping analyses from
lymphocytes of wild type mice. Spleens of the same animals
displayed the expected Gaussian distribution of Vb profiles [4].
CDR3 spectratype in PD-1-/- mice (n=7) showed more than
one Vb peak (Figure 3). Similarly, multiple Vb peaks were visible
in the CNS of PLPtg/PD-1-/- double mutants (n=3) (Figure 3), as
well as in 10 months old PLPtg/PD-1-/- BMCs (n=5). The clonal
expansions occurred widely distributed over different Vb and Jb
regions, although some domains seemed to be prone for clonal
expansions in different mutant mice. Notably, approximately 30%
of the individual clonal expansions were detected in both spleen
and brain, 70% of the expansions were exclusively present in CNS
tissue.
We then sequenced some clones to 1) demonstrate that the
specific PCR fragment represents one TCR (a readable sequence
proves the existence of an expansion), and 2) to detect similarities
between the CDR3s of different clonal expansions. For example,
by analysing the sequences of 2 individuals (mouse A and B) we
identified two expansions with the same VbJb combination and
one expansion with a different VbJb combination in the two mice
(Table S1). While those D segments with flanking N sequences
(=NDN) amino acids, responsible for connecting with the MHC-
bound antigen, show some similarities, the lengths of the CDR3
are not identical, showing that these clones are not specific for the
exact same antigen.
Peripheral immune parameters do not differ between
mutant mouse strains
In order to exclude that peripheral immune parameters in the
mutant mouse strains could account for the different numbers of
immune cells and the aggravated pathological features in double
mutated mice, we analyzed (i) phagocytic capability of macro-
phages, (ii) inducibility and rate of stimulation-induced apoptosis
of splenocytes, (iii) immune subset distribution (CD4+, CD8+,
CD11b+, B220), and (iv) levels of stimulation induced IL-2
production between the different groups (wt, PD-1-/-, PLPtg,
PLPtg/PD-1-/-).
The phagocytic capacity of peritoneal macrophages was similar
in all genotypes. Furthermore, investigation of splenocytes showed
no significant differences between the different genotypes used in
this study in regard of inducibility of apoptosis, cell subsets and
production of cytokines (see Material S1, Figure S1).
CNS T-cells are prone to IFN-c secretion in the absence of
PD-1
Polyclonal immune responses in the periphery do not differ
between mouse mutants. We therefore tested whether CNS cells
show altered production of inflammatory cytokines upon
stimulation. IFN-c secretion of CNS-derived T-lymphocytes was
measured after addition of PMA/ionomycin or upon antigenic
stimulation.
Interestingly, CNS lymphocytes of PD-1-/- and PLPtg/PD-1-/-
mice showed strong IFN-c secretion upon PMA/ionomycin
challenge, while CNS T-cells from PLPtg mice or wt showed
only minimal or no cytokine production (Figure 4A). Of note, such
differences have not been observed in T-cells from spleen
(Figure 4B). Antigenic stimulation with a number of MHC
class I related myelin peptides [4] did not lead to IFN-c
production of CNS T-cells under any condition (ELISPOT, data
not shown).
Discussion
Recent data from human studies in distinct leukodystrophies
and some forms of MS together with investigations in myelin
mutant mice indicate that a primary glial injury can be causative
for neuroinflammation of substantial pathological and
clinical relevance [1,3,4,23,24,25]. Further characterization of
‘‘secondary’’ inflammatory responses in a model of PLP
overexpression identified CD8+ T-lymphocytes of effector cell
phenotype as crucial mediators of demyelination and axon
damage [1]. The finding that CD8+ T-cells in the CNS of myelin
mutants are clonally expanded [4,25] further supports a
Figure 1. Quantification and immunohistochemical detection of CD8+ and CD4+ lymphocytes and CD11b+ macrophage-like cells in
longitudinal sections of optic nerves of wt, PD-1-/-, PLPtg and PLPtg/PD-1-/- mice and of CD8+ cells in bone marrow chimeric mice -
A, B. Quantification of CD8+ lymphocytes in 6 (A: n=3) and 12 (B: n=3–7) months old mice of different genotypes. C. Immunohistochemical
detection of CD8+ lymphocytes in the optic nerve of 12 months old mice of different myelin and immunological genotypes. Arrows indicate
positively labelled CD8+ lymphocytes. D. Quantification of CD4+ lymphocytes in 12 months old mice (n=3–7). Note that in the myelin mutants, both
CD8+ and the generally scarce CD4+ lymphocytes are substantially increased in the absence of PD-1. E. Quantification of CD11b+ macrophage-like
cells in 12 months old mice (n=3–6). Note that the number CD11b+ cells does not differ significantly in PLPtg/PD-1+/+ and PLPtg/PD-1-/- double
mutants. Similar results are obtained in irradiated and non-irradiated (RAG-1-/-) PLPtg bone-marrow recipients. The rather small increase of CD11b+
cells is not surprising, since the molecule in focus (PD-1) is a component of predominantly T-lymphocytes rather than of macrophages/microglial
cells. F. Quantification of CD8+ cells in the CNS of 10 months old PLPtg bone marrow chimeras (BMCs) which were transplanted with either wt or PD-
1-/- bone marrow (n=8–9). Note that also in bone marrow chimeras, CD8+ T-lymphocytes are substantially elevated in the CNS of PLPtg mutants in
the absence of PD-1. Error bars represent standard deviations. * p- value,0.05, ** p - value#0.01. Scale Bar: 50 mm.
doi:10.1371/journal.pone.0004405.g001
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be associated with secondary reactivity of the adaptive immune
system against a still unknown antigen(s). Another key question in
this scenario is which factors control tissue homeostasis of immune
cells. We therefore investigated the impact of immune-regulatory
mechanisms on the adaptive immunity in PLP overexpressing
mutants focussing on the role of the co-inhibitory molecule PD-1.
Recent data in mice as well as in humans demonstrate that PD-1 is
substantially involved in the control of T-cell homeostasis under
physiological and pathological conditions [26] by preventing
Figure 2. Quantification of pathological features in various myelin and PD-1 mutants and BMC mice A. MBP immunohistochemistry of
optic nerve cross sections of 12 months old wt, PD-1-/-, PLPtg and PLPtg/PD-1-/- mice. Note homogeneous MBP distribution in wt and PD-1-/- mice
compared to more disrupted myelin (inhomogeneous labeling) in PLPtg and, more pronounced, PLPtg/PD-1-/- mice. B.-D. MBP immunohisto-
chemistry (B), immunohistochemical detection of CD8+ cells (C) and hematoxylin eosin staining (D) in a plaque like demyelinating lesion in a
12 months old PLPtg/PD-1-/- mouse. Note sharply confined lesion (B) with accumulated T-cells (C) and other, probably inflammatory, cell nuclei (D). E.
Quantification of demyelination by measuring MBP-negative areas. PD-1-deficient myelin mutants (PLPtg/PD-1-/-) show more severe MBP loss than
PLPtg mice expressing PD-1 (PLPtg; n=4–6). F.,G. Semithin optic nerve sections sections of 10 months old PLPtg mice which were transplanted with
wt (F) or PD-1-/- (G) bone marrow. Arrows indicate periaxonal vacuoles which are more numerous in PD-1-/- BMCs. H. Quantification of vacuoles
.6 mm in bone marrow chimeras. PD-1-deficiency leads to the most robust histopathological alterations in the myelin mutants and the most
seriously affected mutants belong to the PD-1-deficient group (n=3–5). * p- value,0.05, ** p - value#0.01. Scale bars: 50 mm.
doi:10.1371/journal.pone.0004405.g002
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dance with these functional data, certain polymorphisms in the
PD-1 gene are associated with human autoimmune disease
including MS [12,28].
Our present experiments show that PD-1 plays a major role in
modulating numbers of CD8+ cells in the demyelinating model of
PLP overexpressing mice.
The most relevant finding of our study was that in PLPtg mice
the histopathological phenotype was much more severe when PD-
1 was absent. Interestingly, not only CNS damage was more
pronounced per individual, but most severely affected individuals
always belonged to the group of PLPtg mice in combination to
functional disruption of PD-1.
How does ablation of the PD-1 pathway affect CNS pathology?
PD-1-deficiency alone only transiently affected the number of
CD8+ cells found in the CNS and, more importantly, the
corresponding mice showed normal histological features in the
CNS. While it has been reported that PD-1-/- mice on a C57/Bl6
Figure 3. Spectratyping of CNS derived lymphocytes - Lymphocytes from the CNS of 12 months old PLPtg (n=7, as adopted from [4], PD-1-/-
(n=7), and PLPtg/PD-1-/- (n=4) mice were analysed for disturbances in the T-cell receptor repertoire by spectratyping. Clonal expansions (visible as
single peaks in the fragment analysis) are shown as colored dots (different colors indicate individual animals). The expanded T-cells are characterized
by their Vb- and Jb-chains. The clonal expansions occurred widely distributed over different Vb and Jb regions, although some domains seemed to be
prone for clonal expansions in different mutant mice. Note that different numbers of experimental mice contribute to the different numbers of dots.
doi:10.1371/journal.pone.0004405.g003
Figure 4. IFN-c ELISPOT assay on spleen and brain derived lymphocytes - IFN-c ELISPOT assay after stimulation with PMA/ionomycin on
CNS derived lymphocytes (A) and splenocytes (B) from wt, PD-1-/-, PLPtg and PLPtg/PD-1-/- mice. Note elevated spot numbers in CNS T-lymphocytes
taken from PLPtg/PD-1-/- mice in comparison to wt and PLPtg mice, reflecting a higher susceptibility to activation. Error bars represent standard
deviations. * p - value,0.05, ** p - value#0.01
doi:10.1371/journal.pone.0004405.g004
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we did not observe any obvious organ pathology, urinal glucose or
protein content (not shown) or spontaneous autoreactions
associated with loss of PD-1. Furthermore, the peripheral immune
‘‘status’’ was not changed in the tested groups (wt, PD-1-/-, PLPtg,
PLPtg/PD-1-/-). However, we found clonal expansions of T-cells
in the periphery in PD-1-/- mice using CDR3 spectratyping
analysis. While numerically not elevated in the CNS at 12 months,
the PD-1-deficient CD8+ cells of PLPwt/PD-1-/- mice showed
multiple clonal T-cell expansions, as opposed to PD-1-expressing
CD8+ cells of normal wild type mice which do not show any
repertoire perturbations. The corresponding CD8+ cells of PLPtg
mice display their characteristic mono- or oligoclonal expansion in
the CNS as previously described [4]. The combination of the PLP
transgene with PD-1 deficiency led to significantly higher numbers
of T-cells within the CNS. Moreover, CD8+ T-lymphocytes of
PD-1 mutants are aberrant with regard of their strong numerical
increase and prominent clonal expansions. This suggests that PD-1
prevents a large number of possible clonal expansions of a variety
of T-cell clones in PLPtg mice. PD-1 signalling is known to
attenuate signals of the T-cell receptor such as PKCtheta and
ZAP-70/CD3f [29]. This could also be the explanation that only
CNS T-cells deficient of PD-1 show markedly enhanced INF-c
secretion after stimulation, whereas CNS CD8+ cells from genuine
PLPtg mice show no relevant production of this proinflammatory
cytokine. These findings suggest that although prominently
expanded and highly susceptible to become activated, PD-1-
deficient T-lymphocytes appear to be pathologically ‘‘silent’’ in a
healthy environment.
Due to its inhibitory properties the cognate ligand PD-L1 has
been proposed to contribute to maintaining peripheral tolerance
and limiting inflammatory damage [20,27,30,31,32]. Parenchymal
PD-L1 contributes to the limitation of insulinitis and the resolution
of inflammation [33]. We and others recently reported that PD-L1
is expressed and upregulated on CNS cells (e.g. microglia cells)
under inflammatory conditions [20,34], restricts parenchymal
neuroantigen-specific T-cell responses and confines inflammatory
CNS damage in experimental autoimmune encephalomyelitis
[35]. One therefore might assume that PD-L1 - PD-1 interactions
counteract T-cell mediated pathology observed in PLPtg mice by
limiting clonal expansion and cytokine release of detrimentally
self-reactive low avidity clones.
A synoptic view summarizing our recent and previous
observations may be as follows: overexpression of PLP may
induce intracellular stress that causes several immune-relevant glial
reactions, such as expression of cytokines and upregulation of
MHC-I molecules on oligodendrocytes [1] and Sn on the surface
of macrophage-like cells. It is of note that the latter reaction is an
important prerequisite for CD8+ cell activation in the present
model [3]. Furthermore, supraphysiological concentrations of
myelin antigens associated with PLP-overexpression could pro-
mote reactivity of low-avidity T-cell clones that survived clonal
deletion or ignorance in the thymus [4]. CNS-derived, but not
spleen-derived CD8+ cells show mono- or oligoclonal expansions,
further suggesting CNS-restricted specificity against yet unidenti-
fied CNS-antigens. PD-1 is critically involved in these processes: in
the presence of PD-1 on CNS CD8+ cells, activation and
proliferation is limited, whereas absence of PD-1 leads to
substantial increase of CD8+ cells, a higher propensity to secrete
proinflammatory cytokines, multiple clonal expansions and an
aggravation of neural damage.
Taken together, our study demonstrates the important role of a
co-inhibitory molecule, PD-1, in modulating glial-injury-related
immune responses in the CNS. This impressively reflects the high
and obviously wide-range relevance of immunmodulatory mech-
anisms under various pathological conditions and should be
particularly considered when seeking for mechanisms leading to
the high clinical variability of polygenic or even monogenic
disorders of the nervous system.
Supporting Information
Figure S1 Exclusion of differences in the peripheral immune
systems of wt, PD-1-/-, PLPtg and PLPtg/PD-1-/- double
mutants. Peritoneal macrophages were incubated with fluorescent
latex beads and the percentage of macrophages which ingested
beads was found similar in all genotypes (A). Differences in the
apoptosis rate were excluded by flow cytometry of annexin V and
PI positive splenocytes under highly stimulatory conditions (B).
Analysis of immune cell subsets (CD4+, CD8+, CD11b+ and
B220+ cells) showed similar distribution in splenocytes of all
investigated genotypes (C). Exclusion of deviations in peripheral
proinflammatory activation using unstimulated and stimulated
splenocytes from different genotypes, by examining IL-2 in the
corresponding supernatants by ELISA (D). Error bars represent
standard deviations.
Found at: doi:10.1371/journal.pone.0004405.s001 (0.39 MB TIF)
Material S1 Material and Methods S1
Found at: doi:10.1371/journal.pone.0004405.s002 (0.03 MB
DOC)
Table S1 CDR3 sequences. Sequencing analysis of two clones
with identical VbJb combinations from PLPtg/PD-1-/- mice A
and B and of one clone with a different VbJb combination from
mouse A. Note identical TCRVb and TCRJb regions surrounding
the CDR3 region, which not only differs in aminoacids but also,
more importantly, in length, thus indicating recognition of
different antigens.
Found at: doi:10.1371/journal.pone.0004405.s003 (0.03 MB
DOC)
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